Literature DB >> 1983390

Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication.

W M Glazer1, H Morgenstern, N Schooler, C S Berkman, D C Moore.   

Abstract

Forty-nine chronic psychiatric out-patients (ten were schizophrenic) with tardive dyskinesia (TD) were examined monthly for a mean of 40 weeks (range 1-59 months) after discontinuation of neuroleptic medication. Complete and persistent reversibility of TD was rare (2%), but many patients showed noticeable improvement in movements within the first year of discontinuation, which was sometimes interrupted by psychological relapse. Using three separate outcome measures and appropriate model-fitting techniques for each, we identified several predictors of improvement in TD, including an affective or schizoaffective psychiatric diagnosis, chronic (over 20 years) psychiatric illness, being employed, younger age, and increased neuroleptic dose before discontinuation. Consistent findings emerging from these analyses suggest that the type and history of psychiatric illness affect the course of TD.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1983390     DOI: 10.1192/bjp.157.4.585

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  21 in total

1.  Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial.

Authors:  Stanley N Caroff; Irene Hurford; Janice Lybrand; E Cabrina Campbell
Journal:  Neurol Clin       Date:  2011-02       Impact factor: 3.806

2.  Tardive dyskinesia: therapeutic options for an increasingly common disorder.

Authors:  Leslie J Cloud; Deepti Zutshi; Stewart A Factor
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

Review 3.  [Antipsychotic-induced tardive syndromes].

Authors:  W Wolfgang Fleischhacker; Alex Hofer; Christian Jagsch; Walter Pirker; Georg Psota; Hans Rittmannsberger; Klaus Seppi
Journal:  Neuropsychiatr       Date:  2016-08-31

4.  Treatment Recommendations for Tardive Dyskinesia.

Authors:  Lucia Ricciardi; Tamara Pringsheim; Thomas R E Barnes; Davide Martino; David Gardner; Gary Remington; Donald Addington; Francesca Morgante; Norman Poole; Alan Carson; Mark Edwards
Journal:  Can J Psychiatry       Date:  2019-02-21       Impact factor: 4.356

5.  Resveratrol Protects Against Vacuous Chewing Movements Induced by Chronic Treatment with Fluphenazine.

Authors:  Alcindo Busanello; Caroline Queiroz Leal; Luis Ricardo Peroza; Jivago Röpke; Elizete de Moraes Reis; Catiuscia Molz de Freitas; Milena Libardoni; Nilda Berenice de Vargas Barbosa; Roselei Fachinetto
Journal:  Neurochem Res       Date:  2017-07-25       Impact factor: 3.996

6.  Effect of alpha lipoic acid on the tardive dyskinesia and oxidative stress induced by haloperidol in rats.

Authors:  Santhrani Thaakur; G Himabindhu
Journal:  J Neural Transm (Vienna)       Date:  2009-05-15       Impact factor: 3.575

Review 7.  Drug-Induced Dyskinesia, Part 2: Treatment of Tardive Dyskinesia.

Authors:  Dhanya Vijayakumar; Joseph Jankovic
Journal:  Drugs       Date:  2016-05       Impact factor: 9.546

Review 8.  Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors.

Authors:  Nicki Niemann; Joseph Jankovic
Journal:  Drugs       Date:  2018-04       Impact factor: 9.546

9.  Effect of spirulina maxima on the haloperidol induced tardive dyskinesia and oxidative stress in rats.

Authors:  S R Thaakur; B Jyothi
Journal:  J Neural Transm (Vienna)       Date:  2007-05-26       Impact factor: 3.575

Review 10.  Anticholinergic medication for antipsychotic-induced tardive dyskinesia.

Authors:  Hanna Bergman; Karla Soares-Weiser
Journal:  Cochrane Database Syst Rev       Date:  2018-01-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.